Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OPKO HealthLTS:0KCS +0.65%48 Cash-to-Debt is 0.76 as of Jun. 2026, which is 55% above its 10-year median of 0.49. GuruFocus rates LTS:0KCS with a GF Score™ of 48/100 and a GF Value™ of $1.12 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, OPKO Health ranks worse than 57.21% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. OPKO Health's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.76.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, OPKO Healthcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for OPKO Health's Cash-to-Debt or its related term are showing as below:
LTS:0KCS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07 Med: 0.49 Max: 1.6
Current: 0.76
During the past 13 years, OPKO Health's highest Cash to Debt Ratio was 1.60. The lowest was 0.07. And the median was 0.49.
LTS:0KCS's Cash-to-Debt is ranked worse than 57.21% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.98
vs LTS:0KCS: 0.76
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
OPKO Health Cash-to-Debt Related Terms
OPKO Health Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for OPKO Health's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
LTS:0KCS vs CSTL, FRNM, FLGT: Cash-to-Debt Comparison
For the Diagnostics & Research subindustry, OPKO Health's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OPKO Health Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where OPKO Health's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPKO Health (LTS:0KCS) has a Cash-to-Debt of 0.76 as of Jun. 2026. This is 55% above median its historical median of 0.49. Over the past decade, OPKO Health's Cash-to-Debt has ranged from 0.07 to 1.60. According to the industry distribution chart, OPKO Health ranks #119 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 57.2%.
Is OPKO Health's Cash-to-Debt too high?
OPKO Health's current Cash-to-Debt of 0.76 is 55% above median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 1.60. The Medical Diagnostics & Research industry median Cash-to-Debt is 0.98. OPKO Health's value of 0.76 is 22.4% below this industry median. Based on the distribution chart, OPKO Health ranks #119 out of 208 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, OPKO Health has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OPKO Health's Cash-to-Debt compare to CSTL and FRNM?
According to the Medical Diagnostics & Research industry distribution chart, OPKO Health ranks #119 out of 208 companies for Cash-to-Debt. This places OPKO Health in the lower half of its industry. The industry median Cash-to-Debt is 0.98. OPKO Health's value of 0.76 is 22.4% below this benchmark. Historically, OPKO Health's own Cash-to-Debt has ranged from 0.07 to 1.60 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 0.98, OPKO Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 0.98, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OPKO Health's current Cash-to-Debt of 0.76 is 22.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OPKO Health's current Cash-to-Debt is 0.76, which is 55% above median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OPKO Health stock overvalued right now?
Based on GuruFocus' analysis, OPKO Health (LTS:0KCS) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.12, compared to a current price of $1.55 — trading 38.4% above its estimated fair value. The current Cash-to-Debt is 0.76, which is 55% above median its 10-year median of 0.49 and 22.4% below the Medical Diagnostics & Research industry median of 0.98. OPKO Health's overall GF Score™ is 48/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For OPKO Health (LTS:0KCS), the current Cash-to-Debt is 0.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OPKO Health (LTS:0KCS) Overvalued in 2026?
Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued.
The current stock price of $1.55 is trading 38.4% above its estimated GF Value™ of $1.12.
GuruFocus considers OPKO Health to be Significantly Overvalued.
Key valuation signals for LTS:0KCS:
Cash-to-Debt: 0.76 (55% above median its 10-year median of 0.49)
GF Value™: $1.12 vs. price of $1.55 (38.4% above fair value)
Industry Position: 22.4% below the Medical Diagnostics & Research median (#119 of 208)
No single metric tells the full story. See the LTS:0KCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
48GF Score
Get the complete analysis for LTS:0KCS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0KCS has been successfully added to your 
